Windlas Biotech (NSE:WINDLAS) Other Current Liabilities: ₹167 Mil (As of Mar. 2026)


NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
92 GF Score
Price ₹829.95
GF Value ₹938.90
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech Other Current Liabilities?

Windlas Biotech NSE:WINDLAS +0.49% 92 Other Current Liabilities is ₹167 Mil as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 92/100 and a GF Value™ of ₹938.90 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Windlas Biotech's other current liabilities for the quarter that ended in Mar. 2026 was ₹167 Mil.

Windlas Biotech's quarterly other current liabilities declined from Sep. 2025 (₹514 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹167 Mil).

Windlas Biotech's annual other current liabilities declined from Mar. 2024 (₹235 Mil) to Mar. 2025 (₹186 Mil) and declined from Mar. 2025 (₹186 Mil) to Mar. 2026 (₹167 Mil).

Windlas Biotech Other Current Liabilities Related Terms

Windlas Biotech Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Other Current Liabilities Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial 170.39 202.62 234.79 186.18 166.55

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 186.18 0.00 514.45 0.00 166.55
NSE:WINDLAS
92GF Score
Windlas Biotech Ltd NSE:WINDLAS
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹167 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Other Current Liabilities of ₹167 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Windlas Biotech.
Is Windlas Biotech's Other Current Liabilities too high?
Windlas Biotech's current Other Current Liabilities is ₹167 Mil. Overall, Windlas Biotech has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Other Current Liabilities compare to ZTS and UTHR?
Windlas Biotech's Other Current Liabilities of ₹167 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Windlas Biotech. Windlas Biotech's current Other Current Liabilities is ₹167 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹938.90, compared to a current price of ₹829.95 — trading 11.6% below its estimated fair value. The current Other Current Liabilities is ₹167 Mil. Windlas Biotech's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Other Current Liabilities is ₹167 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹829.95 is trading 11.6% below its estimated GF Value™ of ₹938.90. GuruFocus considers Windlas Biotech to be Modestly Undervalued.

Key valuation signals for NSE:WINDLAS:

  • Other Current Liabilities: ₹167 Mil
  • GF Value™: ₹938.90 vs. price of ₹829.95 (11.6% below fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
92GF Score

Get the complete analysis for NSE:WINDLAS

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹829.95
Price
₹938.90
GF Value